Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Recent data obtained in animals and in humans suggest that both MAO-A and MAO-B inhibitors present cognitive enhancing properties of possible interest in the treatment of cognitive disorders. In addition, the rational for using selegiline as a neuroprotector in Parkinson's disease may also be applicable in Alzheimer's disease in which a dramatic increase in the MAO-B activity has been reported. It seems then worthwhile to investigate the neuroprotective effect of MAOIs in humans and to assess, furthermore, the real therapeutical benefit of their cognitive enhancing properties.
Delumeau
J C
JC
Laboratory of Experimental and Clinical Pharmacology, University Hospital, Rennes, France.
Bentué-Ferrer
D
D
Gandon
J M
JM
Amrein
R
R
Belliard
S
S
Allain
H
H
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D000818:Animals; D001921:Brain / Q000378:metabolism; D003071:Cognition / Q000187:drug effects*; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology
D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase